
IMMURON
AGM
Nov 2014



Forward-looking Statement

Certain statements made in this presentation are forward-looking statements and are based on Immuron's current expectations, estimates and projections. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements.

Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron's control, including those risks or uncertainties inherent in the process of both developing and commercializing technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements.

The forward-looking statements made in this presentation relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.

Summary upfront

NASH:	Trials are “go ready” An increasingly alluring potential upside
Travelan:	Revenues growing and positioned to grow further
Pipeline:	Progressing
Cap Str:	Robust
Financials:	Debt free, cash in the bank until after completion of NASH trial


Achievements 2014

Improve: Financials and Capital Structure	1. Capital Raise: ~$9.66M 2. Paladin Debt Extinguished 3. Mop Up Unmarketable Parcels 4. Improve Hadassah royalty rates
Progress Operations	5. Increase Travelan Sales & Marketing Activities in Australia 6. Launch of Travelan in Canada 7. Progress Travelan elsewhere 8. "Ready to start" NASH and ASH trials

Robust Capital Structure

	Nov 2013	Nov/Dec 2014
Cash	• <$1M cash at 30 Dec 13	✓ $6M cash at 30 June 14
Debt	• CAD1.5M Paladin Debt owing	✓ Debt Free
Share Register	• 1,800 shareholders on register	✓ ~1,200 SH following Mop Up
	• Share register dispersed	✓ Top 20 own >50%
	• 3B shares on issue	✓ ~75M shares on issue*
Improved Partner Royalties	• Hadasit royalty rates	✓ Improved

* Pending shareholder approval


immuron
2.
TRAVELAN®
ACHIEVEMENTS

Travelan®
Increasing Australian Presence



Sales through pharmacies

Sales & marketing to doctors

Online

Travelan®
Pharmacy



Sales through pharmacies

MARKETING PROGRAM

1. Co-promotion
2. CPD Program
3. Guild Conference

Increasing Sales

Travelan®
Doctors



Sales & marketing to doctors

1. Specialized sales rep
2. Target franchised travel clinics
3. Engage with specialized wholesaler: Equip
4. Engage with KOLs
5. Attend Travel Medicine Conference


Travelan®
Online




1. Upgrade: www.travelan.com.au
2. Online advertising
3. Facebook summer campaign

Online

Travelan®
Succesful Canadian Launch
Exceeding Expectations



Travelan®



* Regulatory application preceding partnering engagement


immuron
3.
NASH/ASH
(INFLAMED
FATTY LIVER)

NASH
What we have done in 2014

Appoint internal team

Update
1. **Protocol**
2. **Investigational Brochure**

Select and Engage with:
1. **Monitors**
2. **Data Management**
3. **MRI analysis (2)**
4. **Liver Biopsy**
5. **Biomarker specimens**

Hospitals
1. **Select and engage with …**
2. **Visit/audit**
3. **Negotiate**
4. **Ethics**

November 2014
Ready to start


February 2014
Capital Raise

Formulation and manufacture of clinical trial material

Central Co-ordination & Analysis



Sites - Australia



Sites – United States





4. PIPELINE

C. Difficile

Progressing to the clinic

A promising program


Continuing Collaboration with Monash

Potential to leverage into other indications


immuron
5.
LOOKING
FORWARD

Looking Forward 2015

Travelan	1. Continue to increase Australian Travelan revenue 2. Increase Canadian Travelan revenue 3. Launch in the US 4. Continue to progress elsewhere overseas
Another Product	4. Launch another product in Australia
NASH	5. Recruit patients and manage recruitment rate 6. Increase profile amongst KOLs, prospective licensees and investment community
C difficile	7. Continue to progress C difficile project


immuron
THANK YOU
Chief Executive Officer
Amos Meltzer
amos@immuron.com